Ocular Therapeutix, Inc.

Based on current plans and related estimates of anticipated cash inflows from DEXTENZA ® , the Company believes that its current cash balance is sufficient to support its planned expenses, debt service obligations, and capital expenditure requirements into 2028.

SEC original ↗Ocular Therapeutix, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Based on its current operating plan which includes estimates of anticipated cash inflows from existing product sales and cash outflows from operating expenses and capital expenditures, the Company believes that its existing cash and cash equivalents of $ 598,641 as of June 30, 2026, will enable it to fund its planned operating expenses, debt service obligations and capital expenditures at least through the next 12 months from the issuance date of these unaudited condensed consolidated financial statements while the Company observes a minimum liquidity covenant of $ 20,000 in its credit facility (Note 7).

SEC original ↗Ocular Therapeutix, Inc. — 10-Q Quarterly report10-QAug 3, 2026

The Company will need to finance its operations through public or private securities offerings, debt financings, collaborations, strategic alliances, licensing agreements, royalty agreements, or marketing and distribution agreements.

SEC original ↗Ocular Therapeutix, Inc. — 10-Q Quarterly report10-QAug 3, 2026

Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: June 30, December 31, 2026 2025 Accrued payroll and related expenses $ 14,170 $ 17,971 Accrued research and development expenses 10,527 14,726 Accrued rebates and programs 6,604 6,245 Accrued professional fees 4,408 2,223 Accrued other 2,634 1,916 Accrued interest payable on Barings Credit Facility (Note 9) 713 754 $ 39,056 $ 43,835 7.

SEC original ↗Ocular Therapeutix, Inc. — 10-Q Quarterly report10-QAug 3, 2026

Financial Liabilities Barings Credit Agreement On August 2, 2023 (the Closing Date ), the Company entered into a credit and security agreement (the Barings Credit Agreement ) with Barings Finance LLC ( Barings ), as administrative agent, and the lenders party thereto, providing for a secured term loan facility for the Company (the Barings Credit Facility ) in the aggregate principal amount of $ 82,474 (the Total Credit Facility Amount ).

SEC original ↗Ocular Therapeutix, Inc. — 10-Q Quarterly report10-QAug 3, 2026

Indebtedness under the Barings Credit Facility matures on the six-year anniversary of the Closing Date.

SEC original ↗Ocular Therapeutix, Inc. — 10-Q Quarterly report10-QAug 3, 2026

“We are entering the most important phase of Ocular Therapeutix’s history, marked by consistent execution, growing clinical conviction, and a clear roadmap to redefine the retina treatment landscape,” said Pravin U.

SEC original ↗Ocular Therapeutix, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

As a result of this clinical strategy, AXPAXLI has the potential to secure an unprecedented superiority label in wet AMD.

SEC original ↗Ocular Therapeutix, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

This change was not an FDA requirement, but rather a strategic decision to further bridge the gap between clinical trial design and clinical practice.

SEC original ↗Ocular Therapeutix, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Building on FDA’s positive feedback received earlier this year, Ocular is actively engaged in defining its clinical strategy for AXPAXLI in NPDR and diabetic macular edema (DME).

SEC original ↗Ocular Therapeutix, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

The Company plans to provide more details surrounding its clinical trial strategy and design at its upcoming Investor Day on September 30, 2025.

SEC original ↗Ocular Therapeutix, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Challenges with current therapies include pulsatile, repeated intraocular injections, treatment-related adverse events and up to 40% patient discontinuation within one year of initiating treatment with continued disease progression.

SEC original ↗Ocular Therapeutix, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements.

SEC original ↗Ocular Therapeutix, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Legal Proceedings 41 Item 1A.

SEC original ↗Ocular Therapeutix, Inc. — 10-Q Quarterly report10-QAug 3, 2026

Exhibits 42 SIGNATURES 45 Table of Contents FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties.

SEC original ↗Ocular Therapeutix, Inc. — 10-Q Quarterly report10-QAug 3, 2026

The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of important factors, including those described in the section titled Risk Factors.

SEC original ↗Ocular Therapeutix, Inc. — 10-Q Quarterly report10-QAug 3, 2026

The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, dependence on specific programs, compliance with government regulations, regulatory approval and compliance, reimbursement, uncertainty of market acceptance of products and the need to obtain additional financing.

SEC original ↗Ocular Therapeutix, Inc. — 10-Q Quarterly report10-QAug 3, 2026